Dr Stephen Rankin
- Clinical Research Fellow (Cardiovascular & Metabolic Health)
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Rankin, S. et al. (2024) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography. bioRxiv, (doi: 10.1101/2024.05.30.596741)
Rankin, S., Elyan, B. , Jones, R. , Venugopal, B., Mark, P. B. , Lees, J. S. , Petrie, M. C. and Lang, N. N. (2024) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, 6(2), pp. 267-279. (doi: 10.1016/j.jaccao.2023.12.010) (PMID:38774021) (PMCID:PMC11103039)
Elyan, B. M.P. , Rankin, S., Jones, R., Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)
Henriksen, P. A., Rankin, S. and Lang, N. N. (2023) Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology Primer. JACC: CardioOncology, 5(3), pp. 292-297. (doi: 10.1016/j.jaccao.2023.05.004) (PMID:37397086) (PMCID:PMC10308056)
Rankin, S., McGuire, J., Chekroud, M., Alakandy, L. and Mukhopadhyay, B. (2022) Evaluating xanthochromia in the diagnosis of subarachnoid haemorrhage in Scotland in the Era of modern computed tomography. Scottish Medical Journal, 67(2), pp. 71-77. (doi: 10.1177/00369330211072264) (PMID:35105220)
Rankin, A. J. and Rankin, S. H. (2017) Cardioverting acute atrial fibrillation and the risk of thromboembolism: not all patients are created equal. Clinical Medicine, 17(5), pp. 419-423. (doi: 10.7861/clinmedicine.17-5-419) (PMID:28974590)
Rankin, S., Elder, D.H., Ogston, S., George, J., Lang, C.C. and Choy, A.M. (2017) Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy. Cardiovascular Therapeutics, 35(3), e12258. (doi: 10.1111/1755-5922.12258) (PMID:28276175)
Ben Batalla, I. et al. (2017) Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia. Clinical Cancer Research, 23(9), pp. 2289-2300. (doi: 10.1158/1078-0432.CCR-16-1930) (PMID:27856601)
Rankin, A. J. , Rankin, S. H. and Rankin, A. C. (2015) Auscultating heart and breath sounds through patients’ gowns: who does this and does it matter? Postgraduate Medical Journal, 91(1077), pp. 379-383. (doi: 10.1136/postgradmedj-2015-133321) (PMID:26183342)
Rankin, S. et al. (2024) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography. bioRxiv, (doi: 10.1101/2024.05.30.596741)
Rankin, S., Elyan, B. , Jones, R. , Venugopal, B., Mark, P. B. , Lees, J. S. , Petrie, M. C. and Lang, N. N. (2024) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, 6(2), pp. 267-279. (doi: 10.1016/j.jaccao.2023.12.010) (PMID:38774021) (PMCID:PMC11103039)
Elyan, B. M.P. , Rankin, S., Jones, R., Lang, N. N. , Mark, P. B. and Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5(7), 100672. (doi: 10.1016/j.xkme.2023.100672) (PMID:37492115) (PMCID:PMC10363559)
Henriksen, P. A., Rankin, S. and Lang, N. N. (2023) Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology Primer. JACC: CardioOncology, 5(3), pp. 292-297. (doi: 10.1016/j.jaccao.2023.05.004) (PMID:37397086) (PMCID:PMC10308056)
Rankin, S., McGuire, J., Chekroud, M., Alakandy, L. and Mukhopadhyay, B. (2022) Evaluating xanthochromia in the diagnosis of subarachnoid haemorrhage in Scotland in the Era of modern computed tomography. Scottish Medical Journal, 67(2), pp. 71-77. (doi: 10.1177/00369330211072264) (PMID:35105220)
Rankin, A. J. and Rankin, S. H. (2017) Cardioverting acute atrial fibrillation and the risk of thromboembolism: not all patients are created equal. Clinical Medicine, 17(5), pp. 419-423. (doi: 10.7861/clinmedicine.17-5-419) (PMID:28974590)
Rankin, S., Elder, D.H., Ogston, S., George, J., Lang, C.C. and Choy, A.M. (2017) Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy. Cardiovascular Therapeutics, 35(3), e12258. (doi: 10.1111/1755-5922.12258) (PMID:28276175)
Ben Batalla, I. et al. (2017) Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia. Clinical Cancer Research, 23(9), pp. 2289-2300. (doi: 10.1158/1078-0432.CCR-16-1930) (PMID:27856601)
Rankin, A. J. , Rankin, S. H. and Rankin, A. C. (2015) Auscultating heart and breath sounds through patients’ gowns: who does this and does it matter? Postgraduate Medical Journal, 91(1077), pp. 379-383. (doi: 10.1136/postgradmedj-2015-133321) (PMID:26183342)